We know how important the Pharma CI Europe conference is to you and your business. As we have grappled with the effect of the Covid-19 coronavirus outbreak on event plans, we have held two principles uppermost in our mind: the health and safety of all attendees, and the high-value experience you count on. Given the recent declaration by the Swiss government to ban all large public events, we believe it is not prudent to go forward with our traditional conference this spring. We are pursuing an alternative approach to provide the benefits you expect across several formats.
Expanded Event Formats
1. We will convene a live Pharma CI Europe Conference in Zurich on November 5-6 at the same venue. This is confirmed so you can adjust travel plans accordingly.
2. We will also convene on March 19 a virtual Pharma CI Conference in webinar format. We will share more details on the webinar program soon.
The coronavirus challenge is unprecedented for us in our decade of serving CI professionals. We want our CI community to thrive, so even as we are prioritizing health by avoiding a large in-person gathering at this time, we are excited to provide new ways for you to share expertise and enhance interaction this month and beyond.
All the best,
The Pharma CI Conference Team
Key to this session will be addressing business needs across the lifecycle, whereby participants will:
* Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
* Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
* Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment
Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.
Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.
Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.
In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.
This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.
When faced with a new product that can be transformational to the field, the key issue becomes understanding the adoption dynamics, identifying the drivers of change within this dynamic, and then building a plan to deliver on transforming the adoption cycle.
Topics we will cover:
• What are the 10 “commandments” to build a successful CI team
• What is needed to make the CI team relevant and impactful for a company
• How to recruit the best CI talent into the department and retain them
The audience can expect to be able to participate actively in the “conversation” and contribute to the program.
One of pharma’s most successful CI professionals reveals 5 questions you must ask at the beginning of each project to ensure:
1. A dramatic return on investment for your CI efforts
2. Be recognized for the impact you are creating in your organization
3. Increase your resources and get your next promotion
In this presentation, Salvador Carlucci clearly demonstrates how CI professionals can educate their stakeholders on how to determine the real value of competitive intelligence and how to capture that value to propel their career. Filled with inspirational stories and practical advice, make sure not to miss this presentation.
With over 30 years at the “sharp-end” of intelligence gathering across the world, one the Co-Founder(s) of Dig Worldwide will provide plenty of real-life anecdotes and experiences. Dig Worldwide’s talk will briefly cover the following:
• Legal and ethical frameworks
• The six techniques that aid competitor-based communications
• Suggestions on how to protect your competitive advantage in the office and other public venues from companies such as Dig Worldwide
The EMA follows various procedural timetables to evaluate potential marketing authorisations, which differ in length and requirements from the US FDA and other agencies. We will present data to help you more accurately predict approval timelines and discuss how this can be supplemented by CI insights to better understand competitors’ launch strategy.
How can we use demographic shifts to help inform new business models? How will digital disruption affect drug development and access? How are mHealth platforms shifting patients’ approaches to healthcare?
Specifically this presentation will enable you to:
* Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
* Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
* Understand Gx / biosimilar product development and entry strategies
* Identify potential actions to optimize launches
A result of this can be dissatisfied end users and low utilization rates. Understanding the value proposition disconnect and developing strategies to better align the two value propositions can improve both patient and sales outcomes.
This session will describe how Win/Loss for the LS market can generate new insights into intermediate and end user decision factors and demonstrate how to adjust the value proposition to improve the match for both end user and purchase decision maker. With a particular emphasis on drug formulary, delivery systems, surgical devices, and medical imaging products, the session will discuss how to design a Win/Loss program for LS, how to interpret Win/Loss findings for strategy development, and how a Win/Loss program of LS differs from typical Win/Loss programs.
Session attendees will gain a deeper understanding of how Win/Loss can apply to LS and drive strategy. Real world (blinded) examples of Win/Loss components (questionnaires, interview excerpts, and analysis reports) will be presented to illustrate the different tools and benefits of a Win/Loss program.
If biopharma companies want to expand in these emerging areas, their strategy must be tailored to the developing pace of change. We will discuss the most promising emerging areas, to lay out the opportunities, challenges and trends that will drive change and explain how CI can help steer organizational strategic success.